Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R. and Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5) (PMID:31844184) (PMCID:PMC7028732)

[img]
Preview
Text
207115.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Background: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant prostate cancer by enhancing the efficacy of docetaxel. Methods: We performed a drug-repurposing screen by using murine-derived prostate cancer cell lines driven by clinically relevant genotypes. Cells were treated with docetaxel alone, or in combination with drugs (n = 857) from repurposing libraries, with cytotoxicity quantified using High Content Imaging Analysis. Results: Mebendazole (an anthelmintic drug that inhibits microtubule assembly) was selected as the lead drug and shown to potently synergise docetaxel-mediated cell killing in vitro and in vivo. Dual targeting of the microtubule structure was associated with increased G2/M mitotic block and enhanced cell death. Strikingly, following combined docetaxel and mebendazole treatment, no cells divided correctly, forming multipolar spindles that resulted in aneuploid daughter cells. Liposomes entrapping docetaxel and mebendazole suppressed in vivo prostate tumour growth and extended progression-free survival. Conclusions: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth. Our data support a new concept of combined mebendazole/docetaxel treatment that warrants further clinical evaluation.

Item Type:Articles
Additional Information:Funding information This work was supported by the Prostate Cancer Foundation Challenge Award (R.P. and H.Y.L.), Cancer Research UK Beatson Institute (C596/ A17196 and CRUK A15151; H.Y.L.), Lister Institute of Preventive Medicine and Wellcome Trust Investigator Award (200870/Z/16/Z; A.S.), Worldwide Cancer Research (16-1303; C.D. and H.Y.L.) and The Dunhill Medical Trust (R463/0216; C.D. and S.S.).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:James, Mr Daniel and Leung, Professor Hing and Hewit, Dr Kay and Patel, Dr Rachana and Shanks, Dr Emma
Authors: Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., and Leung, H. Y.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
Publisher:Springer Nature
ISSN:0007-0920
ISSN (Online):1532-1827
Published Online:17 December 2019
Copyright Holders:Copyright © The Author(s) 2019
First Published:First published in British Journal of Cancer 122:517–527
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record